Korro Bio, Inc. — fact timeline

Korro Bio, Inc. reported first quarter ended March 31, 2026 results: net income $19.6 million.

“Korro’s net loss was $19.6 million for the three months ended March 31, 2026”

Korro Bio, Inc. entered into subscription agreement with a number of institutional accredited investors valued at approximately $85.0 million (effective 2026-03-09).

“Korro Bio, Inc., or Korro, entered into a subscription agreement with a number of institutional accredited investors pursuant to which it agreed to sell and issue in a private placement”

Korro Bio, Inc. announced a restructuring with charges of approximately $2.4 million (approximately 34%).

“On November 12, 2025, Korro implemented a strategic restructuring to extend cash runway, including a workforce reduction of approximately 34%. Korro estimates that it will incur one-time restructuring charges of approximately $2.4 million including employee severance, benefits and related termination costs, the majority of which Korro expects to recognize during the three months ended December 31, 2025.”

Oliver Dolan was appointed as Principal Accounting Officer at Korro Bio, Inc..

“the Company’s Board of Directors appointed Mr. Oliver Dolan, age 42, current Senior Vice President, Finance, to serve as the Company’s principal accounting officer effective March 27, 2025.”

Ram Aiyar changed role as President and Chief Executive Officer at Korro Bio, Inc..

“Dr. Ram Aiyar, who had been serving as the Company’s interim principal financial officer, is no longer serving in that role as of March 27, 2025 and continues to serve as the Company’s President and Chief Executive Officer (principal executive officer).”

Vineet Agarwal was appointed as Chief Financial Officer at Korro Bio, Inc..

“Effective March 27, 2025, Vineet Agarwal, Chief Financial Officer of Korro Bio, Inc., or the Company, ended his temporary medical leave of absence, which had been in effect since February 11, 2025.”

Oliver Dolan was appointed as Interim Principal Accounting Officer at Korro Bio, Inc..

“and Mr. Oliver Dolan, Senior Vice President, Finance, to serve as Korro’s interim principal accounting officer”

Ram Aiyar was appointed as Interim Principal Financial Officer at Korro Bio, Inc..

“Korro’s Board of Directors appointed Dr. Ram Aiyar, President and Chief Executive Officer (principal executive officer), to serve as Korro’s interim principal financial officer”

Vineet Agarwal changed role as Chief Financial Officer at Korro Bio, Inc..

“Effective February 11, 2025, Vineet Agarwal, Chief Financial Officer (principal financial officer and principal accounting officer) of Korro Bio, Inc., or Korro, is taking a temporary medical leave of absence.”

Katharine Knobil, M.D. was appointed as Director at Korro Bio, Inc..

“and then increased the number of directors from six to seven to create a vacancy in Class III and then appointed Katharine Knobil, M.D. to fill the newly created vacancy on the Board in Class III effective immediately.”

David L. Lucchino resigned as Director at Korro Bio, Inc..

“On August 26, 2024, David L. Lucchino, a member of our Board of Directors, or the Board, notified us that he resigned from the Board, effective immediately.”

Steve Colletti resigned as Chief Scientific Officer at Korro Bio, Inc..

“On June 17, 2024, Steve Colletti, Ph.D., notified Korro Bio, Inc. of his intent to resign as its Chief Scientific Officer effective August 2, 2024.”

Korro Bio, Inc. reported first quarter of 2024 results: net income $19.6 million.

“Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2024”

Korro Bio, Inc. entered into Subscription Agreement with a number of institutional accredited investors valued at approximately $70.0 million (effective 2024-04-17).

“On April 17, 2024, we entered into a subscription agreement with a number of institutional accredited investors pursuant to which we agreed to sell and issue in a private placement”